Veradigm - MDRX STOCK NEWS

Veradigm (OTCMKTS: MDRX) announced that Syracuse Orthopedic Specialists has selected its Revenue Cycle Services and Coding Services solutions to enhance their financial operations. The orthopedic care provider, already utilizing Veradigm Revenue Analytics, Practice Management, and Payerpath, aims to optimize revenue cycle management and improve operational efficiency.

The EHR-agnostic healthcare RCM service is designed to reduce accounts receivable days, minimize claim errors, and decrease denials. The Coding Services solution integrates with existing EHR systems to identify deficiencies and optimize coding workflow, focusing on increasing first-pass claims and accelerating revenue generation.

Syracuse Orthopedic Specialists' CEO Mike Humphrey emphasized the decision to extend their partnership with Veradigm, citing the company's expertise in handling billing and reducing staff burden while increasing revenue.

Veradigm (MDRX) has provided financial updates for fiscal 2023, 2024, and an outlook for 2025. For fiscal 2023, the company estimates:

• Revenue: $620-625 million (including $19M in favorable customer settlements)
• GAAP Net Income: $62-65 million
• Adjusted EBITDA: $139-144 million
• Net Cash: $239 million

For fiscal 2024, preliminary estimates show:

• Revenue: $583-588 million
• GAAP Net Loss: $46-49 million
• Adjusted EBITDA: $85-90 million
• Net Cash: $87 million

The company expects 2025 revenue to remain approximately flat compared to 2024, with positive net cash position. Interim CEO Tom Langan expressed confidence in the business model and mentioned focus on remediating material weaknesses and relisting their common stock.

Veradigm (OTCMKTS: MDRX) has filed its Annual Report on Form 10-K for fiscal year 2022, including restated financial statements for periods in 2022, 2021, and 2020. The filing marks a important step toward regaining compliance with financial reporting obligations.

Interim CEO Tom Langan emphasized the company's focus on addressing material weaknesses, remedying internal control deficiencies, becoming current in financial reporting, and working toward relisting their common stock. Interim CFO Lee Westerfield confirmed that the revenue adjustments from continuing operations align with estimates previously disclosed in the Form 12b-25 filed on March 4, 2025.

Veradigm (OTCMKTS: MDRX), a leading healthcare data and technology solutions provider, has scheduled a significant financial update announcement for March 18, 2025, after market hours. The company will follow this with an investor conference call and webcast on March 19, 2025, at 8:00 a.m. Eastern Time.

Investors and interested parties can access the conference call through two methods:

• Online via the Veradigm investor relations website
• By phone: 877-405-1224 or 201-389-0848 (Access ID: 13752381)

The financial update announcement will be available on the company's investor relations website, and a replay of the conference call will remain accessible for one year through the same platform.

Veradigm (OTCMKTS: MDRX) announced that over 3,500 healthcare practices across the United States are now receiving gaps-in-care alerts through their Veradigm Payer Insights solution. The system integrates alerts directly into providers' electronic health records (EHRs), enabling them to address care gaps at the point-of-care.

Healthcare providers can earn approximately $100 per patient gap addressed through payer incentive programs. The solution benefits both payers and providers by improving patient outcomes, reducing staff burden, enhancing clinical decision-making, and improving claims acceptance rates.

For Medicare Advantage plans, closing care gaps can lead to significant savings through improved risk adjustment accuracy, reduced hospitalizations, and increased Star Ratings. The initiative represents Veradigm's ongoing effort to expand its network through payer/provider collaborations.

Veradigm (OTCMKTS: MDRX) has achieved a significant milestone by becoming the first and only electronic health record (EHR) media provider to receive certification from the Point of Care Marketing Association (POCMA) for EHR advertising. The certification, validated by the Alliance for Audited Media through a rigorous annual assessment, demonstrates Veradigm's commitment to transparency in point-of-care marketing.

As a Veradigm Network solution, the Digital Health Media platform enables life science and healthcare industry stakeholders to reach targeted providers within their EHR system. The platform delivers advertisements in a separate iframe window, distinct from clinical workflows, ensuring compliance with applicable laws by not displaying biopharma or device advertisements during prescribing.

Veradigm (OTCMKTS: MDRX) announced that its Board of Directors has approved an amendment to extend its existing Stockholder Rights Plan from February 26, 2025, to August 20, 2025. The amendment updates the exercise price for rights purchase from $50.00 to $32.00.

The extension is driven by ongoing challenges including: the continuing audit of 2022 financial statements, delayed financial reporting due to restatement requirements, and the company's delisted status. The Board noted these factors make tracking share accumulation particularly challenging. The decision was also influenced by a significant stock price decline following the termination of strategic alternatives exploration.

The Rights Plan aims to protect stockholders from potential rapid share accumulations or creeping acquisitions of control without payment of appropriate control premiums. The plan doesn't prevent the company from considering fair offers that benefit stockholders.

Veradigm (OTCMKTS: MDRX) has launched seven new disease-specific cardiometabolic Clinical Data Registry datasets to enhance real-world research capabilities. The registries harmonize data from over 80 different electronic health records (EHRs), combining both structured and unstructured data to provide comprehensive insights into disease patterns and treatment outcomes.

The new registry cohorts include specialized datasets for Heart Failure, Atrial Fibrillation, ASCVD, Hypertension, Type 1 Diabetes, Type 2 Diabetes, and Chronic Kidney Disease. The company utilizes Natural Language Processing (NLP) to extract insights from clinical data, particularly focusing on details relevant to life science researchers, public health, and government regulators.

Veradigm (OTCMKTS: MDRX) has achieved top rankings in Black Book Research's 2025 Top-Rated EHR Vendors by Specialty, securing the #1 position for both Ambulatory EHR Family Practice and Primary Care General Practice categories. The recognition follows a comprehensive nine-month survey involving 33,516 respondents across the United States.

The company's EHR solution received exceptional scores, achieving a 9.3 out of 10 (93% client experience rating), particularly excelling in ease of navigation and telehealth integration. The platform serves tens of thousands of providers nationwide and has recently launched Veradigm Ambient Scribe to further enhance provider experience.

Black Book's evaluation highlighted Veradigm's success in adapting to regulatory changes, improving interoperability, enhancing patient engagement, and streamlining practice workflows. The recognition validates Veradigm's commitment to transforming healthcare through innovative solutions that address provider burnout and support the transition to value-based care.